Baxter‘s net income was $570m for the first quarter 2011, or $0.98 per diluted share, compared to net income of $63m, or $0.11 per diluted share, for the comparable period in 2010.
For full-year 2011, Baxter now expects to achieve sales growth, excluding the impact of foreign currency, of 3 to 4%, and earnings per diluted share, before special items, of $4.20 to $4.28 per diluted share.
For the second quarter of 2011, the company expects sales growth, excluding the impact of foreign currency, of 4 to 5%, and earnings per diluted share of $1.01 to $1.03, before any special items.
Baxter chairman and CEO Robert Parkinson said Baxter’s financial position provides them the flexibility to invest in and pursue opportunities that expand diverse product portfolio with innovative products that save and sustain patient lives and position the company for enhanced growth.